Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHH-1V booster after primary Vaxzevria vaccination
2022-000795-19Phase 2Completed
- Sponsor
- HIPRA
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PHH-1V, tozinameran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by HIPRA. Started Mar 2022; status: completed.
02
Drugs
PHH-1VtozinameranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000795-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000795-19.